Nasdaq notifies Aspire Biopharma of delisting for MVLS and bid price non-compliance; company appeals

Aspire Biopharma Holdings, Inc.

On Oct 15, 2025, Nasdaq Staff notified the Company of delisting due to failure to comply with the MVLS Rule ($50M minimum) and Bid Price Rule ($1.00 minimum).
The Company failed to regain compliance within the 180-day period that ended on October 13, 2025.
The Company requested a hearing before the Nasdaq Hearings Panel and paid a $20,000 fee, which stays the suspension pending the Panel's decision.
The Company will present a plan to regain compliance and may request an extension of up to 180 additional days.
There is no assurance that the Panel will grant continued listing or that compliance can be regained.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.